Clobazam

🧮 Dose calculator

Lennox-Gastaut syndrome · Regimen source: FDA Onfi · 2.1, Table 1

• • ≤30 kg: 5 mg/day, day 7 → 10 mg, day 14 → 20 mg. >30 kg: 10 mg/day, day 7 → 20 mg, day 14 → 40 mg. Above 5 mg/day give in 2 doses. No faster than weekly; taper to stop. FDA Onfi · 2.1, Table 1FDA Onfi · 2.2

Enter age and weight.

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Onfi · 8.1

  “Risk Summary Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see Warnings and Precautions ( 5.9) and Clinical Considerations] .”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Onfi · 8.2

  “Risk Summary ONFI is excreted in human milk ( see Data) .”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Onfi · 8.4

  “Safety and effectiveness in patients less than 2 years of age have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Onfi · 8.5

  “Clinical studies of ONFI did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Onfi · 8.3

  “Administration of clobazam to rats prior to and during mating and early gestation resulted in adverse effects on fertility and early embryonic development at plasma exposures for clobazam and its major active metabolite, N-desmethylclobazam, below those in humans at the MRHD [see Nonclinical Toxicology ( 13.1 )] .”